Breast and Other Cancers in Families with Ataxia-Telangiectasia

New England Journal of Medicine

Volumn 316, Issue 21, 1987, Pages 1289-1294

  Swift, Michael ^a   Reitnauer, Pamela J ^a   Morrell, Daphne ^a   Chase, Charles L ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAXIA TELANGIECTASIA; BREAST; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CLINICAL ARTICLE; DNA REPAIR; ETIOLOGY; GENE FREQUENCY; HEREDITY; HETEROZYGOTE; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0023244806     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198705213162101     Document Type: Article

References (39)

1. Boder E. Ataxia-telangiectasia: an overview. In: Gatti RA, Swift M, eds. Ataxia-telangiectasia: genetics, neuropathology, and immunology of a degenerative disease of childhood. New York: Alan R. Liss, 1985: 1–63.
2. Spector BD, Filipovich AH, Perry GS III, Kersey JH. Epidemiology of cancer in ataxia-telangiectasia. In: Bridges BA, Harnden DG, eds. Ataxia-telangiectasia: a cellular and molecular link between cancer, neuropathology, and immune deficiency. Chichester, England: John Wiley, 1982:103–38.
3. Morrell D, Cromartie E, Swift M. Mortality and cancer incidence in 263 patients with ataxia-telangiectasia. JNCI 1986; 77: 89–92.
4. Narita T, Takagi K. Ataxia-telangiectasia with dysgerminoma of right ovary, papillary carcinoma of thyroid, and adenocarcinoma of pancreas. Cancer 1984; 54: 1113–6.
5. Lambert WC, Kolber LR, Gorelli LA, Muglia JJ, Kardashian JF. Epidermoid carcinoma of the oral cavity following diagnostic roentgenographic examination in a patient with ataxia-telangiectasia. Clin Prev Dent 1982; 4: 3–8.
6. Roifman CM, Gelfand EW. Heterogeneity of the immunological deficiency in ataxia-telangiectasia: absence of a clinical-pathological correlation. In: Gatti RA, Swift M, eds. Ataxia-telangiectasia: genetics, neuropathology, and immunology of a degenerative disease of childhood. New York: Alan R. Liss, 1985:273–85.
7. Taylor AMR. Cytogenetics of ataxia-telangiectasia, In: Bridges BA, Hamden DG, eds. Ataxia-telangiectasia: a cellular and molecular link between cancer, neuropathology. and immune deficiency. Chichester, England: John Wiley, 1982:53–81.
8. Gatti RA, Swift M, eds. Ataxia-telangiectasia: genetics, neuropathology, and immunology of a degenerative disease of childhood. New York: Alan R. Liss, 1985.
9. Bridges BA, Harnden DG, eds. Ataxia-telangiectasia: a cellular and molecular link between cancer, neuropathology, and immune deficiency. Chichester, England: John Wiley, 1982.
10. Cunliffe PN, Mann JR, Cameron AH, Roberts KD, Ward HWC. Radiosensitivity in ataxia-telangiectasia. Br J Radiol 1975; 48: 374–6.
11. Lehmann AR. The cellular and molecular responses of ataxia-telangiectasia cells to DNA damage. In: Bridges BA. Harnden DG, eds. Ataxia-telangiectasia: a cellular and molecular link between cancer, neuropathology, and immune deficiency. Chichester, England: John Wiley, 1982:83–101.
12. Paterson MC, MacFarlane SJ, Gentner NE, Smith BP. Cellular hypersensitivity to chronic γ-radiation in cultured fibroblasts from ataxia-telangiectasia heterozygotes. In: Gatti RA, Swift M, eds. Ataxia-telangiectasia: genetics, neuropathology, and immunology of a degenerative disease of childhood. New York: Alan R. Liss, 1985:73–87.
13. Arlett CF, Priestly A. An assessment of the radiosensitivity of ataxia-telangiectasia heterozygotes. In: Gatti RA, Swift M, eds. Ataxia-telangiectasia: genetics, neuropathology, and immunology of a degenerative disease of childhood. New York: Alan R. Liss, 1985:101–9.
14. Shiloh Y, Tabor E, Becker Y. In vitro phenotype of ataxia-telangiectasia (AT) fibroblast strains: clues to the nature of the “AT DNA lesion” and the molecular defect in AT. In: Gatti RA. Swift M, eds. Ataxia-telangiectasia: genetics, neuropathology, and immunology of a degenerative disease of childhood. New York: Alan R. Liss, 1985:111–21.
15. Shiloh Y, Parshad R, Sanford KK, Jones GM. Carrier detection in ataxia-telangiectasia. Lancet 1986; 1: 689–90.
16. Swift M, Morrell D. Cromartie E, Chamberlin AR, Skolnick MH, Bishop DT. The incidence and gene frequency of ataxia-telangiectasia in the United States. Am J Hum Genet 1986; 39: 573–83.
17. Swift M, Sholman L, Perry M, Chase C. Malignant neoplasms in the families of patients with ataxia-telangiectasia. Cancer Res 1976; 36: 209–15.
18. Swift M, Caldwell RJ, Chase C. Reassessment of cancer predisposition of Fanconi anemia heterozygotes. JNCI 1980; 65: 863–7.
19. Morrell D, Chase CL, Swift M. Cancer and autoimmune disease in families with common variable immune deficiency. Genet Epidemiol 1986; 3: 17–26.
20. Morrell Cancer in families with severe combined immune deficiency. JNCI 1987; 78: 455–8.
21. Kerzin-Storrar L, Faed MJW, MacGillivray JB, Smith PG. Incidence of familial Hodgkin's disease. Br J Cancer 1983; 47: 707–12.
22. Tanaka K, Nishigouri S, Kameda S, et al. Decreased mortality among relatives of patients with systemic lupus erythematosus. Am J Epidemiol 1983; 118: 728–31.
23. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research: principles and quantitative methods. Belmont, Calif.: Lifetime Learning Publications, 1982.
24. Rothman KJ, Boice JD Jr. Epidemiologic analysis with a programmable calculator. Washington, D.C.: National Institutes of Health, 1979. (DHEW publication no. (NIH) 79–1649.)
25. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. JNCI 1959; 22: 719–48.
26. Swift M, Cohen J, Pinkham R. A maximum-likelihood method for estimating the disease predisposition of heterozygotes. Am J Hum Genet 1974; 26: 304–17.
27. Monson RR. Analysis of relative survival and proportional mortality. Comput Biomed Res 1974; 7: 325–32.
28. Young JL Jr. Percy CL, Asir AJ, et al. Surveillance, epidemiology, and end results: cancer incidence and mortality in the United States, 1973–77. Nati Cancer Inst Monogr 1981; 57: 1–187.
29. Gitlin JN, Lawrence PS. Population exposure to X-rays U.S. 1964: a report on the Public Health Service X-ray Exposure Study. Washington, D.C.: Department of Health, Education, and Welfare, 1966:211–3. (DHEW publication no. (PHS) 1519.)
30. Swift M, Chase C. Cancer and cardiac deaths in obligatory ataxia-telangiectasia heterozygotes. Lancet 1983; 1: 1049–50.
31. Comptroller General Report to the Congress of the United States: problems in assessing the cancer risks of low-level ionizing radiation exposure. Vol. 2. Washington, D.C.: General Accounting Office, 1981:14/1–14/6.
32. Kelsey JL. Hildreth NG, Thompson WD. Epidemiologic aspects of breast cancer. Radiol Clin North Am 1983; 21: 3–12.
33. Tokunaga M, Norman JE Jr, Asano M, et al. Malignant breast tumors among atomic bomb survivors, Hiroshima and Nagasaki, 1950–1974. JNCI 1979; 62: 1347–59.
34. Cook DC, Dent O, Hewitt D. Breast cancer following multiple chest fluoroscopy: the Ontario experience. Can Med Assoc J 1974; 111: 406–9, 412.
35. Boice JD Jr, Monson RR. Breast cancer in women after repeated fluoroscopic examinations of the chest, JNCI 1977; 59: 823–32.
36. Howe GR, Miller AB, Sherman GJ. Breast cancer mortality following fluoroscopic irradiation in a cohort of tuberculosis patients. Cancer Detect Prev 1982; 5: 175–8.
37. Shore RE. Hempelmann LH, Kowaluk E, et al. Breast neoplasms in women treated with x-rays for acute postpartum mastitis. JNCI 1977; 59: 813–22.
38. Induction of thyroid cancer by ionizing radiation: recommendations of the National Council on Radiation Protection and Measurements. Bethesda, Md.: National Council on Radiation Protection and Measurement, 1985. (NCRP report no. 80.)
39. Skubic SE, Fatouros pp. Absorbed breast dose: dependence on radiographic modality and technique, and breast thickness. Radiology 1986; 161: 263–70.